NEW YORK (GenomeWeb) – Q2 Solutions, a clinical trials laboratory services organization, said today that it has established a collaboration framework with Illumina for companion diagnostics development.

Under the terms of the agreement, Q2 Solutions will use Illumina's MiSeqDx instrument, which has US Food and Drug Administration 510(k) clearance, to develop next-generation sequencing-based companion diagnostics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.